

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. In the amended claims, additions are shown as underlined and deletions are shown as ~~struck through~~ or in [[double brackets]].

1. (Currently Amended) A crystalline adefovir dipivoxil, characterized in that it has [[a]] characteristic ~~peak peaks~~ expressed in terms of 2θ at about 3.60, ~~and optionally one or more characteristic peaks in terms of 2θ at~~ about 7.28, about 15.08, about 17.24, about 17.96, about 20.12, and about 22.24 in X-ray powder diffraction pattern with Cu target radiation, an endothermic peak at about 94.5°C in DSC thermogram, a melting point at 94°C to 95°C, and peaks at about 3320 cm⁻¹, about 3160 cm⁻¹, about 2975 cm⁻¹, about 1755 cm⁻¹, and about 1650 cm⁻¹ in Fourier Transform Infrared Spectrum.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Previously Presented) A composition comprising the crystalline adefovir dipivoxil of claim 1 and one or more pharmaceutically acceptable carriers or excipients.
6. (Previously Presented) The composition of claim 5 in unit dosage form wherein each dosage unit contains 100-400 mg crystalline adefovir dipivoxil.
7. (Currently Amended) The composition of claim 5 in unit dosage form wherein each dosage unit contains 1-80 mg crystalline adefovir dipivoxil.
8. (Currently Amended) A process for preparing the crystalline adefovir dipivoxil of claim 1, comprising ~~steps as follows:~~

- a. Placing ~~AD~~ adefovir dipivoxil in a round bottom flask;
b. Adding organic solvent and dissolving ~~AD~~ adefovir dipivoxil ultrasonically to form an ~~AD~~ adefovir dipivoxil solution;
c. Spray drying the ~~AD~~ adefovir dipivoxil solution formed by step b ~~above to form a powder~~; and
d. Collecting the powder to obtain the crystalline ~~AD~~ adefovir dipivoxil.
9. (Currently Amended) The process of claim 8, wherein said organic solvent of step (b) is selected from the group consisting of anhydrous ethanol, methanol, acetone, ~~acetonitril/di-n-butyl ether acetonitrile/di-n-butyl ether~~, and methylene chloride and the formed ~~organic~~ adefovir dipivoxil solution has an ~~AD~~ adefovir dipivoxil concentration of 100-300 g/L; in step (c), the inlet air temperature is set at 85-100°C, the measured inlet air temperature is 85-100°C; the measured outlet air temperature is 50-75°C; pump output efficiency is 5-15%; air pump output efficiency is 70%-95%; and the rate of airflow of the air compressor is at 600 L/L-800 L/L.
10. (Currently Amended) The process of claim 8, wherein said organic solvent of step (b) is ethanol and said ~~organic~~ adefovir dipivoxil solution has an ~~AD~~ adefovir dipivoxil concentration of 200 g/L; in step (c), said inlet air temperature is set at 95°C, the measured inlet air temperature is 95°C; the measured outlet air temperature is 60°C; pump output efficiency is 8%; air pump output efficiency is 85%; and the rate of airflow of the air compressor is at 700 L/L.